<DOC>
	<DOCNO>NCT01354808</DOCNO>
	<brief_summary>The purpose study determine whether adjunctive cilostazol loading/maintenance standard treatment ( aspirin , clopidogrel , statin ) effective reduction major adverse cardiovascular event , platelet activation , inflammation myonecrosis patient non-ST-elevation acute coronary syndrome ( ACS ) undergo percutaneous coronary intervention ( PCI ) .</brief_summary>
	<brief_title>ACCEL-LOADING-ACS Study</brief_title>
	<detailed_description>In ACS patient , platelet activation , inflammation , ischemia-reperfusion injury closely associate risk post-PCI myonecrosis ischemic event occurrence . In ACCEL-AMI ( Adjunctive Cilostazol versus high maintenance-dose ClopidogrEL patient Acute Myocardial Infarction ) study , adjunctive cilostazol increase platelet inhibition compare double-dose clopidogrel . Meanwhile , statins reduce extent myonecrosis via limit inflammation myocardial infarct size activate phosphatidylinositol-3-kinase ( PI3K ) , ecto-5'-nucleotidase , Akt/endothelial nitric oxide synthase ( eNOS ) , downstream effector inducible nitric oxide synthase ( iNOS ) cyclooxygenase-2 ( COX-2 ) . Inhibition PI3K , adenosine receptor , eNOS , iNOS , COX-2 abrogate protective effect statin . In animal study , combination low-dose statin cilostazol synergistically limit infarct size . Multiple study show cilostazol influence inflammation RISK pathway use similar pathway statin . This study perform evaluate role adjunctive cilostazol platelet inhibition , inflammation , myonecrosis compare standard treatment .</detailed_description>
	<mesh_term>Reperfusion Injury</mesh_term>
	<mesh_term>Myocardial Reperfusion Injury</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>least 18 year age NonSTelevation ACS patient undergo PCI within 48 hour hospitalization ST segment elevation acute myocardial infarction NSTE ACS highrisk feature warrant emergency coronary angiography Oral anticoagulation therapy warfarin Use preprocedural glycoprotein IIb/IIIa inhibitor Contraindication antiplatelet therapy AST ALT ≥ 3 time upper normal Left ventricular ejection fraction &lt; 30 % WBC &lt; 3,000/mm3 , platelet &lt; 100,000/mm3 Creatinine ≥ 3 mg/dl stroke within 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Cilostazol</keyword>
	<keyword>Platelet</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Myonecrosis</keyword>
</DOC>